ArriVent BioPharma, Inc. - AVBP

Ownership (Schedule 13D / 13G) · latest 50 filings · Back to all files
Visible: 0
Filed Form Reporting person Percent Shares SEC
Oct 13, 2026 SCHEDULE 13G Vivo Opportunity Fund Holdings, L.P. 3.1% 1,514,446 View
Oct 13, 2026 SCHEDULE 13G Vivo Opportunity Co-Invest, L.P. 0.3% 176,752 View
Oct 13, 2026 SCHEDULE 13G Vivo Opportunity Co-Invest (Cycle 3), L.P. 1.6% 781,503 View
Oct 13, 2026 SCHEDULE 13G Vivo Opportunity, LLC 5.0% 2,472,701 View
Oct 13, 2026 SCHEDULE 13G Vivo Opportunity Cayman Fund, L.P. 0.3% 152,971 View
Oct 13, 2026 SCHEDULE 13G Vivo Opportunity Cayman, LLC 0.3% 152,971 View
Oct 08, 2026 SCHEDULE 13D/A — 1.0% — View
Jul 27, 2026 SCHEDULE 13G/A BlackRock, Inc. 6.8% 3,182,080 View
May 06, 2026 SCHEDULE 13G/A FMR LLC 6.8% 3,016,132 View
May 06, 2026 SCHEDULE 13G/A Abigail P. Johnson 6.8% 3,016,132 View
Percent = "% of class represented by amount beneficially owned" for this reporting person in the filed 13D/13G. Shares = reported beneficial ownership amount for the same row (not portfolio shares from 13F). Amendments (/A) can repeat the same holder over time, so rows should not be summed. Extraction is best-effort from filing text and can be missing or noisy; verify exact figures via the SEC link in each row.